Skip to content

Study · Measured the body's own peptide · 2002

1 result

Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.

Itoh H, Naito T, Takeyama M

The Journal of pharmacy and pharmacology1 Nov 2002Cited by 4 (Europe PMC)

PMID12495560 (opens in a new tab)DOI10.1211/002235702117 (opens in a new tab)PepBankPUB-12495560
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialOther

    In healthy male volunteers, the H2-receptor antagonists ranitidine, nizatidine, cimetidine and famotidine did not change plasma VIP levels.

    In plain wordsIn healthy men, four stomach-acid drugs did not change the body's own VIP levels in blood.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePlasma VIP level after H2-antagonist administration
    Study

    n = 5

    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    all H(2)-antagonists did not alter the levels of VIP.
    1 context sentence
    Summary · context
    H(2)-Antagonists or placebo was orally administered to five healthy male volunteers.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.